A Comparison of Five SARS-CoV-2 Molecular Assays With Clinical Correlations

Gary W. Procop, MD, MS,1 Jay E. Brock, PhD,1 Edmunds Z. Reineks, MD,1 Nabin K. Shrestha, MD, MPH,2 Ryan Demkowicz, MD,1 Eleanor Cook, MD,1 Emad Ababneh, MD,1 and Susan M. Harrington, PhD1

From the 1Pathology and Laboratory Medicine Institute and 2Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH.

Key Words: COVID-19; SARS-CoV-2; Nucleic acid amplification tests; Coronavirus

Am J Clin Pathol 2020;XX:1–10
DOI: 10.1093/AJCP/AQAA181

ABSTRACT

Objectives: Comparative assessments of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) molecular assays that have been operationalized through the US Food and Drug Administration’s Emergency Use Authorization process are warranted to assess real-world performance. Characteristics such as sensitivity, specificity, and false-negative rate are important to inform clinical use.

Methods: We compared five SARS-CoV-2 assays using nasopharyngeal and nasal swab specimens submitted in transport media; we enriched this cohort for positive specimens, since we were particularly interested in the sensitivity and false-negative rate. Performance of each test was compared with a composite standard.

Results: The sensitivities and false-negative rates of the 239 specimens that met inclusion criteria were, respectively, as follows: Centers for Disease Control and Prevention 2019 nCoV Real-Time RT-PCR Diagnostic Panel, 100% and 0%; TIB MOLBIOL/Roche z 480 Assay, 96.5% and 3.5%; Xpert Xpress SARS-CoV-2 (Cepheid), 97.6% and 2.4%; Simplexa COVID-19 Direct Kit (DiaSorin), 88.1% and 11.9%; and ID Now COVID-19 (Abbott), 83.3% and 16.7%.

Conclusions: The assays that included a nucleic acid extraction followed by reverse transcription polymerase chain reaction were more sensitive than assays that lacked a full extraction. Most false negatives were seen in patients with low viral loads, as extrapolated from crossing threshold values.

Key Points

• Different molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), all of which have US Food and Drug Administration Emergency Use Authorization (FDA EUA) status, may have different performance characteristics.
• The comparisons of multiple assays for SARS-CoV-2 against one another and a resulting composite standard generate analytic performance characteristics (ie, sensitivity and specificity), which are not required for FDA EUA clearance.
• Patients with low viral loads in the respiratory specimen are more likely to have false-negative results with assays that do not have a nucleic acid extraction step prior to amplification.

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus and the subsequent pandemic has resulted in the need to rapidly deploy molecular diagnostic assays for the detection of infected individuals. Molecular diagnostic assays targeting the SARS-CoV-2 virus have been provided by commercial manufacturers and/or designed in individual laboratories and implemented through the authority of the US Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) Act (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization). Assays that achieve EUA clearance have been assessed through a variety of experiments, including but not limited to an assessment of the lower limit of detection (LoD) and in silico assessment of primer and probe sequences for potential cross-reactivity. Although these and the other FDA EUA requirements are excellent initial means of assessing an assay, there is not a defined LoD that is...
necessary for an assay to achieve EUA status. In addition, analytical and clinical sensitivity and specificity determinations are not required, which is understandable when responding to an emergency.

Laboratories that have had a research interest in severe acute respiratory syndrome coronaviruses have had the opportunity to more thoroughly study test performance characteristics through various primer/probe combinations and concentrations and reaction conditions. Most clinical laboratories, which by necessity have been thrust into SARS-CoV-2 testing, have not had this opportunity, however. Therefore, comparative studies of FDA EUA–cleared molecular tests for SARS-CoV-2 are warranted to more fully understand test performance characteristics.

We, therefore, compared five SARS-CoV-2 molecular assays to one another to determine the sensitivity and specificity of these assays. This comparison was enriched for positive specimens, as we were particularly interested in determining the false-negative rates for these assays, since mischaracterizing an infected patient as coronavirus disease 2019 (COVID-19) negative could have considerable infection prevention implications in the hospital. This comparison also afforded our group the opportunity to compare test characteristics, such as crossing thresholds (Cts), with alternate test results, as well as with the clinical and demographic findings of infected patients.

Materials and Methods

The Cleveland Clinic began testing for SARS CoV-2 using the original, three-target Centers for Disease Control and Prevention (CDC) assay (ie, CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel) on March 12, 2020. Four additional assays (see below) were subsequently assessed in an effort to expand capacity and address requests for more rapid turnaround times. Nasopharyngeal (NP) or nasal swabs were collected by a trained medical practitioner, and most were submitted in universal transport medium (UTM) (Copan Diagnostics) or viral transport media (VTM), respectively; two specimens were submitted in 0.9% normal saline, which was also a validated transport medium. VTM was made by the Cleveland Clinic according to the CDC procedure (SOP #DSR-052-03; https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-Transport-Medium.pdf). All specimens were initially tested by the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel as part of the standard operating procedures for the laboratory. Positive and negative specimens, in an approximate 2:1 ratio, were assessed for the presence of the SARS-CoV-2 virus by the four additional assays described below. Specimens were enrolled as they were received and were not selected based on any clinical characteristics.

A specimen was considered to contain the SARS-CoV-2 virus if the results of two or more of the five tests studied were positive according to the standard operating procedure of the laboratory or the manufacturer’s instructions. Otherwise stated, a positive test from any assay needed to be corroborated by a positive result from any other assay for the specimen to be characterized as containing the SARS-CoV-2 virus. The specimen was considered to not contain the SARS-CoV-2 virus if the results from all the tests were negative or if only a single test was positive (ie, a positive test that was not corroborated by any of the other four tests). Any single positive test results were characterized as false positives.

This study was approved by the Cleveland Clinic Institutional Review Board. Patient confidentiality was protected by storing data in a password-protected file on an internal electronic shared drive accessible only to study team members. This was a single-center study.

Nucleic Acid Amplification Assays

**CDC SARS-CoV-2 RT-PCR Assay**

We used the original, three-target SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test that was developed at the CDC (ie, CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel). This assay targets three separate loci in the SARS-CoV-2 nucleocapsid (N) gene. Commercially available plasmids that contained the N gene were used to determine the limit of detection. In brief, serial dilutions were made that contained known concentrations of the target plasmids. Multiple replicates of these were tested until the concentration wherein 95% (ie, 19/20) of the replicates were detected. This defined the limit of detection, which was found to be 20 copies/µL for upper respiratory specimens and 2 copies/µL for lower respiratory specimens. Internal validation studies, which were more extensive than those required for an FDA EUA submission, were performed prior to the introduction of this test.

For each specimen, 200 µL of clinical specimen in transport media was rendered noninfectious within a biological safety cabinet through the addition of 200 µL of Bacterial Lysis Buffer (Roche Diagnostics). A nucleic acid extract was obtained from 200 µL of the inactivated specimen using the MagNA Pure system (Roche). Then, 5 µL of eluate was added to 15 µL of PCR mastermix for each PCR well. The CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel consisted of four separate RT-PCR assays, three of which
targeted different regions of the virus nucleocapsid (N) gene. The fourth RT-PCR was an amplification control that targeted a portion of the human RNase P gene. Testing was performed on an ABI 7500 or ABI 7500 Fast Dx (Thermo Fisher) using fresh extract that was never frozen. Amplification of all three RT-PCR N gene targets (ie, N1, N2, and N3) was necessary to characterize a specimen as positive. No amplification of all N gene targets in conjunction with amplification of the human control gene was necessary to characterize a specimen as negative. Specimens with amplification of only one or two of the N gene targets were characterized as indeterminate for this study and for simplicity were excluded from further analysis.

**TIB MOLBIOL/Roche z 480 Assay**

The RT-PCR test used in this assay was developed by Roche Diagnostics and TIB MOLBIOL. Internal validation studies were performed before introduction of the test. Commercially available controls containing the envelope (E) gene and the RNA-dependent RNA polymerase (RdRP) gene (Exact Diagnostics; SeraCare) were used to determine the limit of detection, which was found to be 20 copies/µL for upper respiratory specimens. We also performed the other validation studies necessary for the submission of an EAU, since this was a laboratory-developed test.

For each specimen, 200 µL of clinical specimen in transport media was rendered noninfectious within a biological safety cabinet through the addition of 200 µL of Bacterial Lysis Buffer (Roche). A nucleic acid extraction was performed using 200 µL of the inactivated specimen using the MagNA Pure system (Roche). This was the same extract tested originally by the CDC assay but had undergone a single freeze-thaw cycle. The nucleic acid extracts were frozen once prior to testing with the TIB MOLBIOL/Roche z 480 Assay. Then, 10 µL of thawed and homogenized eluate was added to 10 µL of PCR mastermix for each PCR reaction. This test consisted of three separate RT-PCR assays, one that targeted the E gene, one that targeted the RdRP gene, and a third amplification control that targeted a portion of the human RNase P gene. Testing was performed on both the Cobas Z 480 and LightCycler 480 platforms (Roche Diagnostics). Amplification of both the E gene and RdRP gene targets was necessary to characterize a specimen as positive with this assay. Both targets had to be negative with amplification of the human control to characterize a specimen as negative. Specimens with amplification of only one of the two targets were characterized as indeterminate for this study and for simplicity were excluded from further analysis.

**Xpert Xpress SARS-CoV-2 (Cepheid)**

The Xpert Xpress SARS-CoV-2 (Cepheid) assay was performed according to the manufacturer’s guidelines. In brief, the fresh (ie, never frozen) specimen was mixed by vortexing for several seconds, and 300 µL of transport media was transferred to the cartridge sample chamber. The test consisted of a multiplex RT-PCR assay that targeted the SARS-CoV-2 E and N2 genes, as well as a sample processing control. Amplification of the N2 gene was necessary to characterize a sample as positive. Specimens with amplification of the E gene without amplification of the N2 gene are characterized by the manufacturer as a presumptive positive, but these were categorized as positive for the purposes of this study. Both N2 and E genes had to render negative results with amplification of the specimen processing control for a specimen to be characterized as negative.

**Simplexa COVID-19 Direct Kit (DiaSorin)**

The Simplexa COVID-19 Direct Kit (DiaSorin) was performed according to the manufacturer’s guidelines. In brief, 50 µL of fresh (ie, never frozen) clinical specimen in transport media was added to the Direct Amplification Disc sample well after 50 µL of the reaction mix was added to the reaction well. Testing was performed on the LIAISON MDX (DiaSorin). This assay used a multiplex RT-PCR that targeted SARS-CoV-2 ORF1ab and S genes along with an internal amplification control. Amplification of at least one target gene (ie, ORF1ab or S) was necessary to characterize a specimen as positive. Both target genes had to render negative results with amplification of the internal RNA control to characterize a specimen as negative.

**ID Now COVID-19 (Abbott)**

The ID Now COVID-19 (Abbott) assay targets a portion of the RdRp gene within the SARS-CoV-2 genome ([https://www.fda.gov/media/136525/download](https://www.fda.gov/media/136525/download)). This assay was performed according to the manufacturer’s guidelines, which at the time of this study included the testing of transport media (see ID Now COVID-19 [Abbott] original FDA EUA submission). Positive and negative results were provided by the instrument and recorded as provided. In brief, fresh (ie, never frozen) specimens were allowed to reach room temperature before testing. The test base and receiver cartridges were placed in the ID Now devices, and the receiver cartridge was
permitted to warm up. When prompted by the instrument, the foil seal was removed, and 200 μL of well-mixed clinical specimen in transport media was dispensed into the receiver cartridge using the disposable pipettes provided in the kit. After 10 seconds of vigorous mixing, the pipette was removed and the transfer cartridge was used to introduce sample into the test base from the receiver cartridge. The lid was closed and the isothermal amplification was initiated. Results were displayed on the ID Now screen, and the three cartridges were disposed of in accordance with instructions, which minimized the possible release of amplified products. The studies were performed in a biological safety cabinet by qualified clinical laboratory technologists. All three instruments used in this part of the study passed daily positive and negative quality control checks, and the reported results passed internal quality checks.

Clinical Parameters

Medical records were available for 208 of the 239 patients enrolled in the study. Thirty-one patients were non–Cleveland Clinic patients whose records were not available for review. Three residents in clinical pathology reviewed electronic medical records for study participants, and a subset of recorded results was checked by one author (S.M.H.). Patient identifiers were removed at the conclusion of the study. Variables assessed included the patient age, sex, patient status as a caregiver (ie, health care provider [HCP]), date of specimen collection, date of onset of symptoms, and whether the patient was evaluated in an inpatient, outpatient (including telemedicine visits), emergency department (ED), or intensive care unit (ICU) location. The presence or absence of the following clinical parameters at the time of the visit was recorded: fever, cough, nausea or vomiting, diarrhea, and dyspnea. For patients who had a chest roentgenogram or chest computed tomography scan, the presence or absence of pneumonia was recorded as interpreted by a radiologist or attending physician.

Statistical Analysis

Analyses were done using R version 4.0.0.\(^{3}\) Test performance with each assay was evaluated in the entire data set, with indeterminates for each assay excluded. Viral loads (as a multiple of the minimum detectable viral load) were calculated from threshold cycle data based on a method previously described.\(^{4}\) For assays with more than a 10% false-negative rate, associations with false-negative results were examined in multivariable logistic regression models, using the subset of patients with the disease. Days since onset of symptoms was missing for 14 (7%) patients. These were found to be missing completely at random on evaluation of the missing data using the R package \textit{VIM}.\(^{5}\) Missing values were imputed using a method of multivariate imputation by chained equations using the R package \textit{ mice}.\(^{6}\) Initial models included all variables with univariable associations at a level of significance of .2. Variable selection was then done with stepwise backward elimination until only variables significant at a level of .05 remained. Logarithm of the viral load and transport medium was forced into the final model as there was good biological plausibility that they would influence false-negative rates. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using the final model. Graphics were created using the \textit{ggplot2} package.\(^{7}\)

Results

A total of 239 specimens were tested by all methods, with the exception of one specimen that could not be performed on the Xpert Xpress SARS-CoV-2 (Cepheid) because of inadequate specimen volume. Composite analysis demonstrated that 168 specimens contained SARS-CoV-2, whereas 71 specimens did not. The performance characteristics of the five tests are summarized in Table 1.

Test Performance

A total of 234 specimen results were available for assessment of the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel; there were five indeterminate results. There were no false negatives and three false positives when this assay was assessed against a composite standard. In total, 208 specimen results were available for assessment of the TIB MOLBIOL/Roche z 480 assay because of 31 indeterminate results. There were five false-negative results and one false-positive result when this assay was assessed against a composite standard. A total of 238 specimen results were available for assessment of the Simplexa COVID-19 Direct Kit (DiaSorin) assay since one of the specimens in this collection could not be tested due to inadequate volume. There were four false negatives and five false positives when this assay was assessed against a composite standard. In total, 239 specimen results were available for assessment of the Xpert Xpress SARS-CoV-2 (Cepheid) assay since one of the specimens in this collection could not be tested due to inadequate volume. There were four false negatives and five false positives when this assay was assessed against a composite standard. Finally, 239 specimen results were available for assessment of the ID Now COVID-19 (Abbott) assay. There were 28 false negatives and two false positives when this assay was...
assessed against a composite standard. The sensitivities, specificities, and false-negative rates for the five assays are shown (Table 1).

Scatterplots of mean Ct values from the three N gene RT-PCRs from the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel vs days since onset of symptoms with results as determined for each assay indicated with colored circles are shown in Figure 1. For each assay, there was a trend of lower Ct values (higher viral load) closer to the time of onset of symptoms. As days since onset increased, Ct value tended to increase (ie, viral load decreases). False-negative results for the Simplexa COVID-19 Direct Kit (DiaSorin) and ID Now COVID-19 (Abbott) assays tended to occur more frequently as time from onset of symptoms increased and Ct values increased (Figure 1).

Clinical Characteristics

Clinical characteristics of the 208 patients for which clinical information was available are shown in Table 2. The mean age was 49.3 years, and 45.2% were male. Most patients were seen in the outpatient setting (63.9%), followed by those seen in the ED (25.0%). Fewer specimens were collected from patients in the ICU (2.4%) or another inpatient unit (8.7%). More specimens were collected with a nasal swab in VTM (60.9%) compared with an NP swab in UTM (39.1%) due to a national shortage of UTM. Ten (4.8%) patients were asymptomatic. The mean days from onset of symptoms to specimen collection was 8.6, although the standard deviation was large. HCPs represented 38.9% of patients; 96% of specimens collected from HCPs were nasal swab/VTM. Most patients were not severely ill. Only 13.0% were characterized as having pneumonia; 19.2% were admitted to the hospital in a non-ICU setting, and 4.8% were admitted to the ICU.

The proportion of patients with other symptoms is given (Table 2).

Associations With False-Negative Test Results

The Simplexa COVID-19 Direct Kit (DiaSorin) and ID Now COVID-19 (Abbott) assays had false-negative rates exceeding 10%. Because the testing of HCPs occurred at a particular location, the swab type and transport medium used at that location were very strongly correlated with each other; of these, only swab/transport medium was used in multivariable analysis to avoid multicollinearity. On multivariable analysis, log₁₀ viral load (OR, 0.46; 95% CI, 0.29-0.67; \( P < .001 \)) was the only variable significantly associated with false-negative results for the Simplexa COVID-19 Direct Kit (DiaSorin) assay (Table 3). For the ID Now COVID-19 (Abbott) assay, both log₁₀ viral load (OR, 0.32; 95% CI, 0.18-0.50; \( P < .001 \)) and swab/transport medium (OR, 4.95; 95% CI, 1.30-25.30; \( P = .018 \)) remained significantly associated with false-negative results in a multivariable analysis (Table 4).

Discussion

All five SARS-CoV-2 nucleic acid amplification tests were performed on each of the 239 clinical specimens received in transport media in this study (ie, split-sample study), with the exception of one specimen that lacked sufficient residual volume to be performed on the Xpert Xpress SARS-CoV-2 (Cepheid) assay. In total, 168 of the specimens were confirmed to contain the SARS-CoV-2 virus by the demonstration of two or more positive tests (ie, at least two unique assays were positive on the same specimen), whereas 70 specimens

| Test                              | No. of Tests (n = 239)a | Positive Specimens, No. | Negative Specimens, No. | Sensitivity, % | Specificity, % | FN Rate, % |
|-----------------------------------|-------------------------|-------------------------|-------------------------|----------------|---------------|------------|
| CDC 2019 nCoV Real-Time RT-PCR    | 234a                    | 165 0 66 3 100          | 95.7 0                  |
| Diagnostic Panel                  |                         |                         |                         |
| TIB/Rocheb                        | 208a                    | 137 5 65 1 96.5         | 98.5 3.5                |
| Xpert Xpress SARS-CoV-2 (Cepheid) | 238a                    | 163 4 66 5 97.6         | 93.0 2.4                |
| Simplexa COVID-19 Direct Kit (DiaSorin) | 239a              | 148 20 70 1 88.1        | 98.6 11.9               |
| ID Now COVID-19 (Abbott)          | 239a                    | 140 28 69 2 83.3        | 97.2 16.7               |

CDC, Centers for Disease Control and Prevention; FN, false negative; FP, false positive; RT-PCR, reverse transcription polymerase chain reaction; TN, true negative; TP, true positive.

aIn total, 239 tests were performed with 168 containing SARS-CoV-2 and 71 without the virus present by the composite positive standard described. The CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel rendered 234 results and five indeterminates; TIB/Roche, 208 results and 31 indeterminates; Simplexa COVID-19 Direct Kit (DiaSorin), 239 results; Cepheid, 238 results and one unavailable for testing; and Abbott, 239 results.

bTIB MOLBIOL/Roche z 480 Assay.
Figure 1  Scatterplots of crossing threshold (Ct), as a surrogate for viral load, vs the days since onset of symptoms for the five molecular severe acute respiratory syndrome coronavirus 2 assays studied. A, Centers for Disease Control and Prevention assay. B, Cepheid assay. C, Roche assay. D, Abbott assay. E, DiaSorin assay. Performance characteristics (eg, TP, TN) are listed and color coded. The y-axis is on a reversed scale. FN, false negative; FP, false positive; Neg, negative; Pos, positive; TN, true negative; TP, true positive.
were found to not contain the virus by the method described. Although input volume into the nucleic acid amplification reactions for each assay varied, which may affect sensitivity, these assays were all performed according to either our laboratory standard operating procedures or the manufacturer’s guidelines that were current at the time of this study. It is noted that the FDA EUA for the ID Now COVID-19 (Abbott) has subsequently been changed to exclude specimen in transport media as an acceptable substrate for testing with the claim that the dilutional effect of placing the specimen into transport media reduces the sensitivity of the assay. Although this may be true, such a dilutional effect would be the same for all assays included in this comparison. We, therefore, conclude that this is a sound assessment of the analytical sensitivity and specificity of these assays. The comprehensive design and assessment of the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel is available for further review, which, like our study, describes the excellent sensitivity and specificity of this assay. Similarly, a thorough evaluation of the components of the TIB MOLBIOL/Roche z 480 assay is available for those interested in further reading. It has been our experience that the elevated indeterminate rate experienced for the TIB MOLBIOL/Roche z 480 assay in this study does not reflect the indeterminate rate of this assay in routine practice. The only difference in this study and routine use was a single freeze-thaw cycle, which we hypothesize may have contributed to this elevated rate through target degradation. The excellent performance of the Xpert Xpress SARS-CoV-2 (Cepheid) assay described in this study is like that described in multicenter trials by others. A comparison between the Xpert Xpress SARS-CoV-2 (Cepheid) and the standard-of-care RT-PCR for SARS-CoV-2 demonstrated a 99.5% positive percent agreement and a 95.8% negative percent agreement, with the majority of discrepant results resolved by a third RT-PCR in favor of the Xpert Xpress SARS-CoV-2 (Cepheid). The assays that lacked a nucleic acid extraction step produced more false-negative reactions than assays that included this step in our study. Although there are a variety of reasons for different amplification efficiencies between assays, such as primer design and nearest neighbor influences, among others, the presence of amplification inhibitors is a common cause of decreased efficiency or even inhibition in assays that begin with a simple lysis step rather than purified nucleic acid extract. Wilson et al demonstrated this by examining the same concentration of target and the same amplification assay after processing by several different methods. An eloquent study by Fung et al determined the analytical limits of detection for seven nucleic acid amplification SARS-CoV-2 assays using material quantitatively characterized using digital droplet PCR. In this study, the Roche cobas, Abbott m2000, and Hologic Panther Fusion assays had lower limits of detection than both the Simplexa COVID-19 Direct Kit (DiaSorin) assay and the ID Now COVID-19 (Abbott) assay. Importantly, the variable performance of the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel was related to the type of extraction used. The Simplexa COVID-19 Direct Kit (DiaSorin) assay has also been assessed in a number of studies. Two of these demonstrated a greater sensitivity or positive percent agreement compared with that described here. This is likely explained by the significant number of patients entering convalescence in our cohort, which was similar to that described by Lieberman et al. The limited comparative sensitivity of the ID Now COVID-19 (Abbott) has been described by others. A comparison of the ID Now COVID-19 (Abbott) with the Abbott RealTime SARS-CoV-2 assay (Abbott) on the m2000 showed an overall positive percent agreement of only 75%. Similarly, Basu et al reported that the Abbott ID Now COVID-19 missed one-third of the specimens that tested positive by the Xpert Xpress SARS-CoV-2 assay (Cepheid) when using nasopharyngeal swabs.
in viral transport media, similar to our study, and a positive percent agreement of 45% when dry nasal swabs were tested directly.

To understand how these assays might perform in our diverse patient population, the specimens tested in the study were not selected from any particular population or based on any set of clinical characteristics. Rather, they were a true representation of the specimens received in the laboratory at the time of the study. Outpatients represented the majority of those tested, and as such, the presence of pneumonia, hospital admission, and ICU stay were relatively low in frequency. Different results might be obtained in a population of individuals with more severe illness.

Our study included a high proportion (38.9%) of HCPs, some of whom were tested more than 2 weeks after onset of illness when viral loads would presumably be declining. Specimens were collected from HCPs in the outpatient setting with nasal or nasopharyngeal swabs and submitted in VTM. The swab/transport medium was a variable chosen for inclusion in the multivariate analysis, as we were interested in ensuring that there were no effects of locally produced transport medium not detected in initial validation studies. However, we noted that the graphs of Ct vs days from onset to specimen collection demonstrate the correlation of decreasing viral load as number of days from first symptoms increases (Figure 1). If some HCPs were tested as symptoms were waning, it stands to reason that lower viral loads were detected and false negatives would be likely.

Use of nasal swab/VTM predominated as the NP swab/UTM collection kit was in short supply, and the latter was preferentially used for inpatients and those seen in the ED. In our study, the use of nasal swab/VTM was independently associated with false-negative results in the ID Now COVID-19 (Abbott) assay. As the swab

| Table 3 | Associations With False-Negative Results for the Simplexa Coronavirus Disease 2019 Direct Kit (DiaSorin) Assay |
|---------|--------------------------------------------------------------------------------------------------|
| Clinical Variable | True Positives | False Negatives | OR (95% CI) | OR (95% CI) |
| Age, mean (SD), y | 51.5 (17.6) | 41.1 (14.1) | 0.96 (0.92-0.99, P = .023) | — |
| Sex | Male 60 (47.2) | 5 (27.8) | 2.33 (0.82-7.61, P = .128) | — |
| Specimen/medium | Female 67 (52.8) | 13 (72.2) | — | — |
| NP/UTM | 52 (40.9) | 3 (16.7) | 3.47 (1.08-15.51, P = .059) | 2.30 (0.53-11.04, P = .215) |
| Nasal/VTM | 75 (59.1) | 15 (83.3) | — | — |
| Fever | No 60 (47.2) | 10 (55.6) | 0.72 (0.26-1.93, P = .510) | — |
| Cough | Yes 67 (52.8) | 8 (44.4) | — | — |
| Nausea or vomiting | No 35 (27.6) | 8 (44.4) | 0.48 (0.17-1.34, P = .148) | — |
| Diarrhea | Yes 92 (72.4) | 10 (55.6) | — | — |
| Dyspnea | No 118 (92.9) | 17 (94.4) | 0.77 (0.04-4.50, P = .811) | — |
| Yes 9 (7.1) | 1 (5.6) | — | — | — |
| CXR | No 100 (78.7) | 16 (88.9) | 0.46 (0.07-1.76, P = .324) | — |
| Done 27 (21.3) | 2 (11.1) | — | — | — |
| Pneumonia | No 102 (80.3) | 17 (94.4) | 0.40 (0.11-1.18, P = .122) | — |
| Yes 25 (19.7) | 1 (5.6) | — | — | — |
| Admitted | No 101 (79.5) | 17 (94.4) | 0.24 (0.01-1.26, P = .175) | — |
| Yes 26 (20.5) | 1 (5.6) | — | — | — |
| ICU | No 120 (94.5) | 17 (94.4) | 0.23 (0.01-1.19, P = .160) | — |
| Yes 7 (5.5) | 1 (5.6) | — | — | — |
| Log viral load, mean (SD) | 4.4 (1.9) | 2.1 (1.6) | 1.01 (0.05-6.18, P = .994) | — |

CI, confidence interval; CXR, chest roentgenogram; ICU, intensive care unit; NP, nasopharyngeal; OR, odds ratio; UTM, universal transport medium; VTM, viral transport media; —, variable eliminated through stepwise analysis process.

*Values are provided as number (%) unless otherwise indicated.
type and transport medium were always used together, it is difficult to distinguish independent effects of each component. As discussed above, the dilutional effect of transport medium may have affected sensitivity, but other considerations that may affect compatibility must also be considered. For the Simplexa COVID-19 Direct Kit (DiaSorin) assay, although transport medium was associated with false-negative results on univariable analysis, the association was not significant on multivariable analysis when adjusted for viral load.

### Conclusion

The findings from the clinical correlation are consistent with the presence of high viral loads (lower Ct values) at the onset of symptoms. This pattern of high viral shedding at symptom onset has been demonstrated by others and is a significant factor in transmission of SARS-CoV-2. Our data suggest that the CDC 2019 nCoV Real-Time RT-PCR Diagnostic Panel, TIB MOLBIOL/Roche z 480 Assay, and Xpert Xpress SARS-CoV-2 (Cepheid) assays perform well at any stage of illness. However, the Simplexa COVID-19 Direct Kit (DiaSorin) and ID Now COVID-19 (Abbott) assays had false-negative rates exceeding 10%, with false-negative results associated with low viral loads, suggesting that they are likely to perform less well when viral loads are lower, which is generally later in the course of illness. This finding concerning the ID Now COVID-19 (Abbott) has been confirmed by others.

Corresponding author: Gary W. Procop, MD, MS; procopg@ccf.org

| Clinical Variable                  | True Positives | False Negatives | OR (95% CI)  |
|-----------------------------------|----------------|----------------|--------------|
|                                   |                |                | Univariable  | Multivariable |
| Age, mean (SD), y                 | 51.7 (17.8)    | 43.1 (14.6)    | 0.97 (0.94-0.99, P = .025) | —            |
| Sex                               | 57 (47.9)      | 8 (30.8)       | 2.07 (0.86-5.38, P = .116) | —            |
| Specimen/medium                   | 52 (43.7)      | 3 (11.5)       | 5.95 (1.94-26.05, P = .005) | 4.95 (1.30-25.30, P = .018) |
| Fever                             |                |                |              |              |
| No                                | 30 (25.2)      | 13 (50.0)      | 0.34 (0.14-0.81, P = .015) | —            |
| Yes                               | 89 (74.8)      | 13 (50.0)      |              |              |
| Nausea or vomiting                |                |                |              |              |
| No                                | 111 (93.3)     | 24 (92.3)      | 1.16 (0.17-4.98, P = .860) | —            |
| Yes                               | 8 (6.7)        | 2 (7.7)        |              |              |
| Cough                             |                |                |              |              |
| No                                | 94 (79.0)      | 22 (84.6)      | 0.68 (0.19-1.99, P = .518) | —            |
| Yes                               | 25 (21.0)      | 4 (15.4)       |              |              |
| Dyspnea                           |                |                |              |              |
| No                                | 69 (58.0)      | 19 (73.1)      | 0.51 (0.19-1.25, P = .158) | —            |
| Yes                               | 50 (42.0)      | 7 (26.9)       |              |              |
| CXR                               |                |                |              |              |
| Not done                          | 77 (64.7)      | 20 (76.9)      | 0.55 (0.19-1.40, P = .235) | —            |
| Done                              | 42 (35.3)      | 6 (23.1)       |              |              |
| Pneumonia                         |                |                |              |              |
| No                                | 94 (79.0)      | 25 (96.2)      | 0.15 (0.01-0.77, P = .070) | —            |
| Yes                               | 25 (21.0)      | 1 (3.8)        |              |              |
| Admitted                          |                |                |              |              |
| No                                | 93 (78.2)      | 25 (96.2)      | 0.14 (0.01-0.73, P = .062) | —            |
| Yes                               | 26 (21.8)      | 1 (3.8)        |              |              |
| ICU                               |                |                |              |              |
| No                                | 112 (94.1)     | 25 (96.2)      | 0.64 (0.03-3.83, P = .683) | —            |
| Yes                               | 7 (5.9)        | 1 (3.8)        |              |              |
| Log viral load, mean (SD)         | 4.6 (1.8)      | 1.9 (1.4)      | 0.32 (0.19-0.49, P < .001) | 0.32 (0.18-0.50, P < .001) |

CI, confidence interval; CXR, chest roentgenogram; ICU, intensive care unit; NP, nasopharyngeal; OR, odds ratio; UTM, universal transport medium; VTM, viral transport media; —, variable eliminated through stepwise analysis process.

Values are provided as number (%) unless otherwise indicated.
Acknowledgments: We thank the following individuals for their significant contribution to this project: Miranda Carver, Ryan Collison, Frank Mularo, Drew Payto, Christine Ramsey, Colleen Starkey, Hillary van Heule, and Sherilynn Vogel.

References

1. US Food and Drug Administration. Emergency Use Authorization. 2020. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas. Accessed June 19, 2020.

2. Lu X, Wang L, Sakthivel SK, et al. US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26:1654-1665.

3. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. https://www.rproject.org/.

4. Shrestha NK, Marco Canosa F, Nowacki AS, et al. Distribution of transmission potential during non-severe COVID-19 illness [published online June 29, 2020]. Clin Infect Dis.

5. Kowarik A, Templ M. Imputation with the R Package VIM. J Stat Softw. 2016;74:1-16.

6. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1-67.

7. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer-Verlag; 2016.

8. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA informs public about possible accuracy concerns with Abbott ID NOW point-of-care test. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point. Accessed June 20, 2020.

9. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:200045.

10. Loefelholz MJ, Alland BS, Butler-Wu SM, et al. Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 test. J Clin Microbiol. 2020. DOI: 10.1128/JCM.00926-20.

11. Wolters F, van de Bovenkamp J, van den Bosch B, et al. Multicenter evaluation of Cepheid Xpert® Xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. J Clin Virol. 2020;128:104426.

12. Wilson D, Yen-Lieberman B, Reischl U, et al. Comparison of five methods for extraction of Legionella pneumophila from respiratory specimens. J Clin Microbiol. 2004;42:5913-5916.

13. Fung B, Gopez A, Serrvetita V, et al. Direct comparison of SARS-CoV-2 analytical limits of detection across seven molecular assays. J Clin Microbiol. 2020;58:e01535-20.

14. Lieberman JA, Pepper G, Naccache SN, et al. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol. 2020. DOI: 10.1128/JCM.00821-20.

15. Rhoads DD, Cherian SS, Roman K, et al. Comparison of Abbott ID now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol. 2020;58:e00760-20.

16. Zhen W, Manji R, Smith E, et al. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens. J Clin Microbiol. 2020;58:e00743-20.

17. Basu A, Zinger T, Inglma K, et al. Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City Academic Institution. J Clin Microbiol. 2020;58:e01136-20.

18. Harrington A, Cox B, Snowdon J, et al. Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients. J Clin Microbiol. 2020;58:e00798-20.

19. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672-675.

20. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-469.